A 5-year follow-up study on the efficacy and safety of ultrasound-guided laser ablation in elderly patients with papillary thyroid microcarcinoma: A retrospective, single-center study from China.
A 5-year follow-up study on the efficacy and safety of ultrasound-guided laser ablation in elderly patients with papillary thyroid microcarcinoma: A retrospective, single-center study from China.
复制标题
对超声引导激光消融的疗效和安全性为期5年的随访研究，对甲状腺乳头状甲状腺微核心瘤的老年患者：一项回顾性的，来自中国的回顾性单中心研究。
DOI：
10.3389/fendo.2022.972589
复制
发表时间：
2022
影响因子：
5.2
通讯作者：
中科院分区：
文献类型：
--
作者：
本研究旨在评价超声引导下经皮激光消融治疗老年甲状腺微小乳头状癌(PTMC)的远期疗效和安全性。自2015年9月至2017年4月，对38例经细针抽吸活检术(FNAB)确诊的老年PTMC患者应用聚乳酸治疗。治疗前评估结节的位置、体积及患者的症状。治疗后24小时行超声造影(CEUS)检查，评价消融的完备性。分别于治疗后1、3、6、12个月及以后每6个月进行超声检查，以评估消融区的体积及复发或转移情况。对于任何可疑的复发或转移病灶，均行FNAB。经超声心动图证实，38例患者全部消融成功。未发现明显并发症。单次消融成功率为100%。平均随访时间64.58±5.29个月(60~78个月)。最后一次随访时，31个(81.58%)消融灶完全消失，7个(18.42%)消融灶有疤痕样改变。结节体积由术前的40.69±16.45 mm~3降至术后42个月的0.22±0.76 mm~3，消融4年后全部消失(P<0.01)。术后6个月、12个月、18个月、24个月、30个月、36个月和42个月的平均体积缩小率分别为12.09%、31.21%、50.9%、72.06%、84.79%、95.65%和100%。在所有入选的患者中，1例(2.6%)局部复发，再次接受聚乳酸治疗。未发现治疗后的结节再生长、淋巴结转移和远处转移。超声引导下经皮冠状动脉腔内成形术是治疗老年PTMC患者安全有效的方法。
The aim of this study is to evaluate the long-term efficacy and safety of ultrasound-guided percutaneous laser ablation (PLA) for the treatment of elderly patients with papillary thyroid microcarcinoma (PTMC). From September 2015 to April 2017, 38 elderly patients with PTMC confirmed through fine-needle aspiration biopsy (FNAB) were treated with PLA. Before the treatment, the location and volume of the nodule together with the patients’ symptoms were evaluated. Twenty-four hours after the treatment, contrast-enhanced ultrasound (CEUS) was performed to evaluate the completeness of the ablation. To evaluate the volume of the ablation area and recurrence or metastasis, ultrasound examination was performed at 1, 3, 6, and 12 months after the treatment and every 6 months thereafter. FNAB was performed for any suspicious recurrence or metastasis lesions. The ablation of all the 38 patients was all achieved completely as confirmed by CEUS. No obvious complications were found. The success rate of single ablation was 100%. The average follow-up time was 64.58 ± 5.29 months (60–78 months). By the time of the last follow-up, 31 (81.58%) ablation lesions disappeared completely and seven (18.42%) ablation lesions showed scar-like changes. The volume of nodules was 40.69 ± 16.45 mm3 before operation, which decreased to 0.22 ± 0.76 mm3 by the end of 42 months, and all nodules disappeared 4 years after ablation (P < 0.01). At 6, 12, 18, 24, 30, 36, and 42 months after ablation, the average volume reduction rates (VRRs) were 12.09%, 31.21%, 50.9%, 72.06%, 84.79%, 95.65%, and 100%, respectively. Of all the patients enrolled, one patient (2.6%) had local recurrence and was treated with PLA again. No regrowth of treated nodule or lymph node metastasis and distant metastases was detected. Ultrasound-guided PLA is effective and safe for the treatment of elderly patients with PTMC who are ineligible for surgery.
登录
查看更多内容
DOI：
10.1089/thy.2017.0227
发表时间：
2018-01
期刊：
Thyroid : official journal of the American Thyroid Association
影响因子：
--
作者：
Miyauchi A;Ito Y;Oda H
通讯作者：
Oda H
影响因子：
3.7
作者：
Lang, Brian Hung-Hin;Wong, Carlos K. H.
通讯作者：
Wong, Carlos K. H.
影响因子：
5.2
作者：
Shi, Yi-Fan;Zhou, Ping;Liang, Yong-Ping
通讯作者：
Liang, Yong-Ping
影响因子：
3.8
作者：
Nickel B;Brito JP;Moynihan R;Barratt A;Jordan S;McCaffery K
通讯作者：
McCaffery K
影响因子：
5.8
作者：
Zhao, Zhen-Long;Wei, Ying;Yu, Ming-An
通讯作者：
Yu, Ming-An